Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report

• Published in: Medicine (Baltimore) 2019-11, Vol.98 (46), p.e17778-e17778
• Main Authors: Wang, Guannan, Jiang, Sujing, Li, Zhouqi, Dong, Ying
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - therapeutic use; Bone Neoplasms - secondary; Clinical Case Report; Denosumab - administration & dosage; Denosumab - therapeutic use; Giant Cell Tumor of Bone - drug therapy; Giant Cell Tumor of Bone - pathology; Giant Cell Tumor of Bone - surgery; Humans; Lung Neoplasms - secondary; Male; Spinal Neoplasms - drug therapy; Spinal Neoplasms - pathology; Spinal Neoplasms - surgery; Sunitinib - administration & dosage; Sunitinib - therapeutic use
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000017778

Giant cell tumor of bone with pulmonary and bone metastases is exceedingly rare in adolescents. Furthermore, Denosumab and Sunitinib in the treatment of giant cell tumor of bone has never been reported. A 16-year-old boy complained of fever, chest tightness, and shortness of breath and back pain for 5 days. Giant cell tumor of bone with pulmonary and bone metastases. The patient underwent 2 surgeries for giant cell tumor of bone located in the spine and received Denosumab to reduce local recurrence and control the metastases. Then Sunitinib was added into treatment strategies after the progressing of metastases. Within 5 months of Denosumab and Sunitinib, lung metastases were shrinking (stable disease, response evaluation criteria in solid tumors version 1.1). Until now about 4 years into treatment the patient is still survival. Pulmonary and bone metastases are stable. This is a case of multi-center giant cell tumor of bone, it does not only provide a reference to the treatment of similar cases of the clinic but also reflects the limitations of the application of Denosumab in the real world.